The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BTOG 2020 | Liquid biopsy: a new era

Name: Liquid biopsy: a new era
Uploaded: 2020-01-31T00:00:00Z
Duration: 2 min 20 s
Description: Samreen Ahmed, FRCP, MD, University Hospitals of Leicester, UK, talks on liquid biopsy technology, measurable residual disease (MRD) and the use of these techniques to aid earlier intervention. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

Samreen Ahmed • 31 Jan 2020

BTOG 2020

Lung Cancer

Samreen Ahmed, FRCP, MD, University Hospitals of Leicester, UK, talks on liquid biopsy technology, measurable residual disease (MRD) and the use of these techniques to aid earlier intervention. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.